Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Czarnetzki BM | [Mediators and the bronchial system. Pathophysiologic and biochemical aspects of mediators of the bronchial system]. | 1987 | Wien Med Wochenschr Suppl | pmid:3078398 |
Keck M et al. | Pathophysiology of burns. | 2009 | Wien Med Wochenschr | pmid:19652939 |
Chmiel B | [The influence of select pathophysiologic factors of acute pancreatitis on erythrocytes' deformability examined in vitro]. | 2002 | Wiad. Lek. | pmid:12715347 |
Guan Z et al. | [Role of interleukin-6 and platelet-activating factor in delaying neutrophil apoptosis]. | 2000 | Wei Sheng Yan Jiu | pmid:12725051 |
Robeva R et al. | [Changes in blood coagulation in glomerulonephritis]. | 1982 | Vutr Boles | pmid:6219496 |
Denizot Y and Nathan N | Platelet-activating factor in operative salvaged blood. | 1994 | Vox Sang. | pmid:7801619 |
Silliman CC et al. | Stored blood components contain agents that prime the neutrophil NADPH oxidase through the platelet-activating-factor receptor. | 1992 | Vox Sang. | pmid:1332255 |
Sieunarine K et al. | Plasma levels of the lipid mediators, leukotriene B4 and lyso platelet-activating factor, in intraoperative salvaged blood. | 1992 | Vox Sang. | pmid:1333134 |
Shebzukhov IuV and Mysiakin EB | [Platelet activating factor--role in regulating the functional activity of the mononuclear phagocyte system]. | 1996 Oct-Dec | Vopr. Med. Khim. | pmid:9254510 |
Muzia GI et al. | [Inhibition of formation of superoxide radicals in leukocytes of hypercholesteremic patients under the effect of a lipid platelet activation factor antagonist]. | 1995 Jul-Aug | Vopr. Med. Khim. | pmid:8571587 |